



MONDAY 15 APRIL 2024 | 08:30–09:00 AM UTC-3 | Hall C2

Breakfast will be provided

# Evolving care for people with CKD: the role of SGLT2 inhibitors

## OBJECTIVES

Highlight the guideline recommendations regarding regular risk assessment and first-line therapy, such as SGLT2 inhibitors, for people living with CKD

Review the evidence for use of SGLT2 inhibitor therapy for people with CKD

Discuss the practical management considerations when using SGLT2 inhibitor therapy for the treatment of people living with CKD and broader use for people with heart failure, renal and metabolic conditions

**Roberto Pecoits-Filho (Brazil)**

Arbor Research Collaborative  
for Health, Michigan, USA



**Adeera Levin (Canada)**

St. Paul's Hospital,  
Vancouver, Canada



TIME

CONTENT

SPEAKERS

08:30–08:33

Welcome and introduction

Roberto Pecoits-Filho

08:33–08:57

Illuminating the evolving care  
for people with CKD: spotlight  
on SGLT2 inhibitors

Roberto Pecoits-Filho  
and Adeera Levin

08:57–09:00

Summary and close

Roberto Pecoits-Filho